Search company, investor...
Search

Predict your next investment

WPP company logo
Corporation
BUSINESS PRODUCTS & SERVICES | Advertising, Marketing & PR
wpp.com

See what CB Insights has to offer

Investments

63

Portfolio Exits

25

Partners & Customers

10

About WPP

WPP (LSE: WPP) (NASDAQ: WPPGY) is an advertising and public relations company that engages in marketing and communications services. The company provides a range of advertising and marketing services including advertising and media investment management, data investment management, public relations and public affairs, branding and identity, healthcare communications, direct, digital, promotion, and relationship marketing, and specialist communications. The company was founded in 1971 and is based in London, U.K.

WPP Headquarters Location

27 Farm Street

London, England, W1J 5RJ,

United Kingdom

+44 (0)20 7408 2204

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

WPP Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

WPP Rank

Latest WPP News

Amid massive turnover, Agios hires Biogen alum as new CFO; Scholar Rock, Everest Medicines lead the big CEO parade

Sep 23, 2022

Ce­cil­ia Jones When Ce­cil­ia Jones start­ed at Gen­zyme, there was next to noth­ing in Kendall Square. “It was just us,” Jones said. “There wasn’t much to even go for lunch.” Jones would work in Cam­bridge, MA, for the next 17 years — spend­ing sev­en at Gen­zyme and 10 at Bio­gen, where she would go on to hold a VP role in fi­nance — as Kendall Square and Cam­bridge grew in­to a biotech hub. “It’s like night and day,” Jones said of the area now. On Mon­day, Jones will re­turn to Cam­bridge as the CFO of Agios, fol­low­ing a two-year stint at Log­icBio (lo­cat­ed less than 10 miles out­side Cam­bridge). Jones joins Agios as the biotech is go­ing through a pe­ri­od of con­tin­u­ous churn. In late 2020, Agios an­nounced it was sell­ing off its en­tire can­cer port­fo­lio , in­clud­ing Tib­so­vo, an AML drug. Since then, it has piv­ot­ed to rare dis­eases, start­ing with Pyrukynd, a drug for pyru­vate ki­nase de­fi­cien­cy, which got its first ap­proval in Feb­ru­ary of this year . In May, amid a larg­er mar­ket down­turn, Agios laid off some 50 em­ploy­ees , and then in Ju­ly, its CSO Bruce Car de­part­ed. Soon af­ter, Jack­ie Fouse hand­ed the CEO seat to Bri­an Goff, as Fouse tran­si­tioned to board chair. When asked about the turnover at Agios, Jones said, “I asked them the same ques­tions.” But for Jones, Agios’ new look as a rare dis­ease biotech was an at­tract­ing fac­tor. She first worked in rare dis­eases at Gen­zyme, where she said she de­vel­oped her pas­sion for the field. “To me, be­ing part of an or­ga­ni­za­tion that has the po­ten­tial to make this pos­i­tive im­pact on peo­ple with rare and ge­net­i­cal­ly-de­fined dis­eases is in­cred­i­bly re­ward­ing. Ob­vi­ous­ly I don’t dis­cov­er drugs, I don’t work in the lab, but I sup­port the groups that do that,” Jones said. On Goff com­ing on as CEO, Jones said, “That was ac­tu­al­ly one of the things that at­tract­ed me to the job too, is Bri­an has a lot of rare dis­ease ex­per­tise and com­mer­cial ex­pe­ri­ence with launch­ing rare dis­ease drugs, so I think he was a per­fect fit to try to lead the com­pa­ny in the next phas­es.” Jones moved to the US in 2000 to get her MBA from Har­vard Busi­ness School. Af­ter grad­u­at­ing, she de­cid­ed to stay in the US and land­ed her first job at Gen­zyme. “I had no back­ground in biotech and had nev­er worked in phar­ma or any­thing like that,” Jones said. “It was a com­plete­ly new chal­lenge for me. And this was al­so 20 years ago — I feel like biotech has be­come much more pop­u­lar and much more known.” “In Ar­genti­na,” Jones said, where she grew up, “def­i­nite­ly, biotech was very nascent, and no­body knew much about it.” But Jones has stayed with the Boston-area biotechs. “I ques­tion that every win­ter,” Jones joked. She then added, “I’ve stayed very loy­al to Mass­a­chu­setts. I still have my Ar­genti­na roots, and I do go back home every year, but it’s been 22 years now.” — Lei Lei Wu Jay Back­strom → Schol­ar Rock founder Nagesh Ma­han­thap­pa took it up­on him­self to fill in as CEO when Tony Kings­ley ul­ti­mate­ly left for Ver­sant pro­tein sta­bi­liza­tion biotech Sta­blix. But he’ll soon roll out the wel­come mat for new chief ex­ec­u­tive Jay Back­strom, the R&D chief at Ac­celeron be­fore Mer­ck’s $11.5 bil­lion M&A play last year. The ex-Cel­gene CMO and head of glob­al reg­u­la­to­ry af­fairs al­so adds to his col­lec­tion of board ap­point­ments, which in­cludes Au­to­lus Ther­a­peu­tics, Be Bio­phar­ma, Disc Med­i­cine and La­va Ther­a­peu­tics. When Back­strom gets set­tled on Oct. 20, Ma­han­thap­pa will re­lin­quish his seat on the board of di­rec­tors and be­come a strate­gic ad­vi­sor. Rogers Yongqing Luo → Ever­est Med­i­cines has quick­ly filled the CEO slot that Ker­ry Blan­chard left va­cant in late Au­gust. Rogers Yongqing Luo had spent the last two years as pres­i­dent and gen­er­al man­ag­er for Greater Chi­na at Brii Bio­sciences, and he helped get eight drugs past the fin­ish line as Ever­est part­ner Gilead’s glob­al VP and Chi­na gen­er­al man­ag­er. In June, Ever­est cel­e­brat­ed its Trodelvy ap­proval in Chi­na, and Gilead then shelled out $280 mil­lion up­front for rights to the drug in Chi­na and se­lect coun­tries in Asia. Ten days af­ter the deal was made, Blan­chard called it quits . Mark Rothera → Mark Rothera has resur­faced as pres­i­dent and CEO of San Diego can­cer biotech Virac­ta Ther­a­peu­tics. In Feb­ru­ary, Rothera stepped aside as chief ex­ec­u­tive of UK RNAi play­er Si­lence Ther­a­peu­tics and left his CFO, Craig Tooman, in charge with lit­tle ex­pla­na­tion, but our Max Gel­man in­di­cat­ed that Tooman’s M&A cre­den­tials could’ve been a fac­tor in his ap­point­ment. Si­lence has cy­cled through a num­ber of CEOs in the last five years, from Ali Mor­taza­vi to David Horn Solomon (now with Pharnext) to Rothera’s ap­point­ment in Sep­tem­ber 2020 af­ter his stint as CEO of Or­chard Ther­a­peu­tics. Virac­ta’s lead pro­gram, a com­bi­na­tion of na­nati­no­s­tat and val­gan­ci­clovir (nana-val), is in a Phase II tri­al for re­lapsed/re­frac­to­ry Ep­stein-Barr virus-pos­i­tive lym­phoma. Abi­gail Jenk­ins → A new era has dawned at Gami­da Cell, where Ju­lian Adams is re­tir­ing and Abi­gail Jenk­ins has re­placed him as pres­i­dent and CEO. For­mer­ly the chief com­mer­cial and busi­ness of­fi­cer at Lyn­dra Ther­a­peu­tics, Jenk­ins was busi­ness unit head of vac­cines at Emer­gent BioSo­lu­tions, ex­it­ing the Bal­ti­more com­pa­ny just as things re­al­ly start­ed to go side­ways with the pro­duc­tion of J&J’s Covid-19 jab. Gami­da Cell’s de­ci­sion day with the FDA on its cell ther­a­py omidu­bi­cel is Jan. 30, 2023. Am­ber Tong has more on Adams’ re­tire­ment . Matthias Alder → Gain Ther­a­peu­tics has pro­mot­ed Matthias Alder to CEO, as Er­ic Rich­man con­cen­trates on his du­ties as a board mem­ber and se­nior ad­vi­sor. As we point­ed out at the time, Alder came to the pro­tein mis­fold­ing biotech al­most a year ago as COO, mov­ing on from his CBO post at Au­to­lus. From 2014-17, he was EVP, busi­ness de­vel­op­ment & li­cens­ing, gen­er­al coun­sel and cor­po­rate sec­re­tary for Su­cam­po Phar­ma­ceu­ti­cals. Rich­man is a 12-year Med­Im­mune vet who took over as Gain’s CEO in Ju­ly 2020 and guid­ed the Bethes­da, MD biotech to its mod­est IPO in March 2021, but its stock $GANX has tak­en a beat­ing ever since, an un­sur­pris­ing turn of events in the cur­rent bear mar­ket. Jodie Mor­ri­son → There’s a chang­ing of the guard at Q32 Bio, now team­ing up with Hori­zon on the an­ti-IL-7Rα an­ti­body ADX-914: At­las Ven­ture part­ner Jodie Mor­ri­son has been named act­ing CEO as for­mer Goldfinch Bio ex­ec Michael Brox­son walks out the door. Mor­ri­son — the for­mer chief ex­ec­u­tive at Ca­dent Ther­a­peu­tics un­til it was sold to No­var­tis — takes a seat on the board and she’ll al­so pre­side over Q32 Bio’s pro­gram for com­ple­ment dis­or­ders, ADX-097, which is in an ear­ly-stage tri­al. → One week re­moved from ex-Tril­li­um chief Jan Skvar­ka’s ap­point­ment to the board of di­rec­tors, Zen­tal­is has poached Car­rie Brown­stein from Cel­lec­tis, nam­ing her CMO. While she was med­ical chief at Cel­lec­tis, Brown­stein start­ed her tenure in­aus­pi­cious­ly when a pa­tient death prompt­ed a clin­i­cal hold of the French biotech’s off-the-shelf CAR-T drug for mul­ti­ple myelo­ma, a study that would re­sume four months lat­er. Brown­stein, a for­mer se­nior med­ical di­rec­tor at Roche and a Re­gen­eron on­col­o­gy vet, was VP of glob­al clin­i­cal R&D dur­ing her three years at Cel­gene. Piyush Shar­ma → Al­ny­lam has made a pair of ap­point­ments as it claims a win with patisir­an in AT­TR amy­loi­do­sis with car­diomy­opa­thy. Piyush Shar­ma (chief ethics & com­pli­ance of­fi­cer) is a Pfiz­er alum who was head of com­pli­ance at Alex­ion once it be­came part of the As­traZeneca uni­verse. And Evan Lipp­man (Al­ny­lam’s first chief cor­po­rate de­vel­op­ment and strat­e­gy of­fi­cer) says good­bye to Alessan­dro Ri­va’s crew at In­ti­ma Bio­science, where he was pres­i­dent and COO. Dur­ing a four-year run with Take­da, Lipp­man served as SVP, head of cor­po­rate de­vel­op­ment, M&A and val­u­a­tion. Eliseo Sali­nas → Eliseo Sali­nas’ next land­ing spot is with Delix Ther­a­peu­tics, the Boston neu­ro biotech that launched in 2019 and nabbed $70 mil­lion in Se­ries A fi­nanc­ing al­most ex­act­ly a year ago. Sali­nas, who signed on as R&D chief at Delix, had the same ti­tle at Pas­sage Bio and split the scene in the midst of a re­org in March that re­fo­cused the pipeline and shaved off 13% of the staff. (CEO Bruce Gold­smith would lat­er step down.) In May 2021, Sali­nas took over as in­ter­im med­ical chief when Gary Ro­mano re­signed mere days af­ter CFO Richard Mor­ris al­so de­cid­ed to pack his bags. Pri­or to his time at Pas­sage Bio, Sali­nas was CSO at Shire and Aca­dia Phar­ma­ceu­ti­cals. Lisa French → Pulled to the sur­face from the quick­sand of bank­rupt­cy and opi­oid lit­i­ga­tion, Mallinck­rodt has re­cruit­ed Lisa French as chief com­mer­cial of­fi­cer af­ter last week’s FDA ap­proval of ter­li­pressin. French re­places Hugh O’Neill and comes from Mer­ck spin­off Organon, where she was the US women’s health busi­ness unit lead. She had a near­ly 30-year ca­reer with the phar­ma gi­ant that con­clud­ed as as­so­ciate VP, US mar­ket­ing lead for the HPV fran­chise be­fore her move to Organon. Brand­ed as Ter­li­vaz, ter­li­pressin earned the OK for adults with he­pa­tore­nal syn­drome, but it does come with a black box warn­ing. Shu­lamit Ron-Big­ger → Ak­tis On­col­o­gy is on easy street — first house down — fol­low­ing an $84 mil­lion raise in late Au­gust , and as the ra­dio­phar­ma­ceu­ti­cals space con­tin­ues to heat up, Matthew Ro­den’s squad has in­stalled Shu­lamit Ron-Big­ger as COO. Leav­ing Big Phar­ma be­hind, Ron-Big­ger had led strat­e­gy and op­er­a­tions for Bris­tol My­ers Squibb’s re­search and ear­ly de­vel­op­ment or­ga­ni­za­tion. Glenn Pauly → As Alzheon touts its Alzheimer’s drug ALZ-801 with­out any clin­i­cal da­ta to show for it — and the Fram­ing­ham, MA biotech has a pen­chant for pat­ting it­self on the back a bit too hard with the da­ta it does gath­er — it’s en­list­ed Glenn Pauly as head of com­mer­cial. Pauly has fa­mil­iar­i­ty with the space from his days at Bio­gen, where he was US west­ern di­vi­sion gen­er­al man­ag­er and VP in charge of com­mer­cial­iza­tion for the ill-fat­ed Alzheimer’s drug Aduhelm. Af­ter hold­ing sales roles at Genen­tech from 2008-17, Pauly be­came As­traZeneca’s se­nior di­rec­tor, mar­ket ac­cess, res­pi­ra­to­ry bi­o­log­ics. Gem­ma Brown → As­traZeneca’s Covid-19 part­ner Vac­citech has el­e­vat­ed Gem­ma Brown to CFO af­ter a year as the Ox­ford spin­out’s head of fi­nan­cial re­port­ing. Brown had pre­vi­ous­ly held a num­ber of roles, in­clud­ing se­nior man­ag­er at EY from 2012-21. De­spite As­traZeneca’s clash with the EU on sup­ply is­sues, and con­cerns over blood clots with the Covid-19 vac­cine it co-in­vent­ed, Vac­citech’s IPO ex­ceed­ed nine fig­ures in April 2021, but its stock $VACC is down more than 75% since its Nas­daq de­but. Re­gard­ing the de­vel­op­ment of Vaxzevria, As­traZeneca CEO Pas­cal So­ri­ot told the BBC in June, “I don’t think I would do any­thing dif­fer­ent­ly from what we did.” Phillip Samayoa → Com­ing off a ma­jor let­down with its he­mo­phil­ia A gene ther­a­py in which shares were rout­ed, Gen­er­a­tion Bio has pro­mot­ed Phillip Samayoa to chief strat­e­gy of­fi­cer. When he was a prin­ci­pal at At­las Ven­ture from 2016-18, Samayoa co-found­ed Gen­er­a­tion Bio and Dyne Ther­a­peu­tics, join­ing Gen­er­a­tion Bio’s team as se­nior di­rec­tor (and then VP) of strat­e­gy and port­fo­lio de­vel­op­ment. Af­ter co-found­ing Co­di­ak Bio­Sciences dur­ing his time at Flag­ship Pi­o­neer­ing, Samayoa jumped over to Mer­ck as di­rec­tor of MRL Ven­tures Fund. → To start this month, Ash­leigh Palmer’s Proven­tion Bio took out a $125 mil­lion loan with Her­cules Cap­i­tal be­fore the FDA reach­es a ver­dict on the BLA re­sub­mis­sion for an­ti-CD3 type 1 di­a­betes drug teplizum­ab. This week the New Jer­sey biotech has lined up NI­BR hu­man re­sources vet Sarah O’Brien as chief peo­ple of­fi­cer. The for­mer head of HR in North Amer­i­ca for So­bi, O’Brien had been chief peo­ple of­fi­cer be­fore with Re­lay Ther­a­peu­tics and, since last year, Arde­lyx. Proven­tion is try­ing to get off the mat with teplizum­ab af­ter re­ceiv­ing a CRL for the ex-Eli Lil­ly drug in Ju­ly 2021. Cindy Cao → Cindy Cao has re­placed Bill Tente as chief reg­u­la­to­ry of­fi­cer of Hu­ma­cyte, al­though Tente will stick around at the Lau­ra Nikla­son-led re­gen­er­a­tive med­i­cine shop as an ex­ec­u­tive ad­vi­sor. She had led reg­u­la­to­ry af­fairs and qual­i­ty as­sur­ance at As­cen­t­age Phar­ma since 2018, but Cao has plen­ty of Big Phar­ma ex­pe­ri­ence from Sanofi, No­vo Nordisk and Bris­tol My­ers. One more quick note: For­mer Air Force Sur­geon Gen­er­al Bruce Green has joined Hu­ma­cyte’s board of di­rec­tors. → Re­turn­ing from a near­ly two-year break that he de­scribed on his LinkedIn as, “Re­tired. Golfed. Shaved a few strokes off my hand­i­cap,” ex-Shire HR chief Pe­ter Lasky is mak­ing all the clutch putts as chief peo­ple of­fi­cer of Waltham, MA an­ti­body biotech Dy­nam­i­Cure. Be­fore he worked on his game, Lasky was SVP, hu­man re­sources at De­ci­phera and the chief HR of­fi­cer at Wave Life Sci­ences. Oliv­er Ernst → Neuway Phar­ma, which is work­ing on new ways of de­liv­er­ing drugs to the brain,  is ush­er­ing in some new changes to its ex­ec team with the pro­mo­tion of Oliv­er Ernst to CEO and the ap­point­ment of Thomas Christoph as chief de­vel­op­ment of­fi­cer. Ernst joined Neuway in 2019 as COO and man­ag­ing di­rec­tor — hav­ing for­mer­ly served in roles at Brain­lab and BASF. Ernst takes over the reins from co-founder, Heiko Man­ninga, who will con­tin­ue to serve as CSO and man­ag­ing di­rec­tor. Mean­while, Christoph joins the Ger­man com­pa­ny from Grue­nen­thal, where he led phar­ma­col­o­gy and pre­clin­i­cal de­vel­op­ment teams. Ruth Thieroff-Ek­erdt → Ag­ing-fo­cused Cam­bri­an Bio­Phar­ma has pulled in Ruth Thieroff-Ek­erdt as EVP of clin­i­cal de­vel­op­ment. Thieroff-Ek­erdt for­mer­ly served as sci­en­tif­ic ad­vi­sor at Organon and act­ing CMO at Foren­do. Her ca­reer al­so spans stints as CMO at So­journix, Ap­tal­is, Strong­bridge and Kalei­do and R&D roles at Bay­er. → Uni­ver­sité Li­bre de Brux­elles spin­off Neu­VasQ Biotech­nolo­gies has locked in Em­manuel Lacroix as CEO and com­pa­ny di­rec­tor. Lacroix hails from UCB Ven­tures, where he was found­ing VP and part­ner. Ear­li­er in his ca­reer, Lacroix was with UCB and Cel­lec­tis. Beth Burn­side → Austin, TX-based Maxwell Bio­sciences has brought aboard three new ex­ecs with the ap­point­ments of Tony Ver­co (CMO), Beth Burn­side (SVP of R&D strat­e­gy), and Don­ald Trea­cy (SVP, de­vel­op­ment op­er­a­tions). Ver­co joins up with the team at Maxwell with ex­pe­ri­ence un­der his belt from roles at Shel­ton Clin­i­cal Re­search Con­sul­tants, Med­well Cap­i­tal, End­point Re­search and As­traZeneca. Mean­while, Burn­side has had gigs at Low­ery Creek Con­sult­ing, QRx­Phar­ma, Mid­dle­Brook Phar­ma­ceu­ti­cals and Shire; while Trea­cy has served at Magothy Con­sult­ing Group (CEO), Mid­dle­Brook Phar­ma­ceu­ti­cals (SVP of de­vel­op­ment and man­u­fac­tur­ing op­er­a­tions), and Shire (se­nior di­rec­tor of an­a­lyt­i­cal sci­ences). Scott Chap­lin → Berke­ley Lights is bring­ing in some fire­pow­er with the ap­point­ment of Scott Chap­lin as chief le­gal of­fi­cer and cor­po­rate sec­re­tary. Chap­lin joins from Shield AI, where he was chief le­gal and peo­ple of­fi­cer. Pri­or to Shield, Chap­lin was with Vista Out­door, Al­liant Tech­sys­tems and Stan­ley. → CD­MO Vi­ro­Cell has brought on Su­san Nichols as CBO. Nichols cur­rent­ly has a seat on the board of the Al­liance for Re­gen­er­a­tive Med­i­cine. Nichols brings with her ex­pe­ri­ence from her time as an ex­ec­u­tive of­fi­cer at Pro­pel Bio­Sciences and CEO of Fal­con Ther­a­peu­tics. Sek Kathire­san → Ja­son Colo­ma’s Maze Ther­a­peu­tics has re­served space for Verve Ther­a­peu­tics CEO Sek Kathire­san on the board of di­rec­tors. Verve’s Phase Ib tri­al is on­go­ing with its car­dio­vas­cu­lar drug — a sin­gle base ed­i­tor named VERVE-101 — and Kathire­san’s crew has teamed up with Ver­tex in a gene edit­ing deal worth $60 mil­lion up­front. → Charles Baltic is suc­ceed­ing Chris­tine White as chair of MEI Phar­ma’s board. A board mem­ber at the San Diego can­cer biotech since 2011, Baltic had been a se­nior ad­vi­sor with Need­ham & Com­pa­ny, where he was al­so man­ag­ing di­rec­tor and co-head of health­care bank­ing. Er­ic Ende → Er­ic Ende will take over for Her­bert Con­rad as chair­man of Mati­nas Bio­Phar­ma on Oct. 1, al­though Con­rad will stay on the board. Ende, an ex-Mer­rill Lynch biotech an­a­lyst, al­so sits on the boards of Avadel Phar­ma­ceu­ti­cals and NeuBase Ther­a­peu­tics. → One of the few biotechs will­ing to brave the Nas­daq el­e­ments with an IPO this year , Pep­Gen has wel­comed Habib Dable to the board of di­rec­tors. This is the third time in as many months that the for­mer Ac­celeron CEO has popped up in this part of Peer Re­view af­ter board ap­point­ments at Blue­print Med­i­cines and Al­bireo. Lau­ren Sil­ver­nail → Un­der the lead­er­ship of CEO Julie East­land, Har­poon Ther­a­peu­tics has elect­ed ex-Re­vance CFO and CBO Lau­ren Sil­ver­nail to the board of di­rec­tors. The Al­ler­gan vet just spent four years as CFO and EVP of cor­po­rate de­vel­op­ment at Evo­lus. → Win­ston Kung is head­ed to the board of di­rec­tors at Mer­ck’s T cell en­gager part­ner Janux Ther­a­peu­tics. Kung is a Cel­gene vet who han­dles the roles of COO and CFO at p53 biotech PMV Phar­ma. → CNS-fo­cused Pa­sithea Ther­a­peu­tics has brought in ex-Biosense CEO Al­fred No­vak to the board of di­rec­tors af­ter Yas­sine Ben­di­a­b­dal­lah’s ex­it. Last week, Pa­sithea named Mer­it Cud­kow­icz to its sci­en­tif­ic ad­vi­so­ry board. AUTHORS Nicole DeFeudis Editor Weeks after announcing the spinoff of generics arm Sandoz, Vas Narasimhan paints a picture of the new, slimmer Novartis — with a “US-first mindset,” he said at an investor event on Thursday. The CEO unveiled ambitious plans to become a top-five player in the US by 2027 at Novartis’ “Meet the Management” event in Basel, Switzerland, which means ramping up clinical trials in the states and “building capability and talent, among other things.” The company’s also shooting for a top-three ranking in China. Keep reading Endpoints with a free subscription Unlock this story instantly and join 150,700+ biopharma pros reading Endpoints daily — and it's free. SIGN UP Beth Snyder Bulik Senior Editor If pharma advertising had a fantasy football league, Pfizer would be crushing the competition. A dive into the National Football League’s TV commercial buys across early season games by iSpot shows a hefty lead with its Covid-19 Comirnaty vaccine ads. More than 175 million impressions with $9.5 million in media spending put Pfizer in the top spot with a 65% share of voice across NFL pharma spending, according to the real-time TV ad tracker. In a distant second place is Bristol Myers Squibb’s Opdivo with 44 million impressions, $5.2 million in spending and a 16% share, followed by BMS’ Zeposia with 31 million impressions, $3.3 million in media buys and an 11% share. Keep reading Endpoints with a free subscription Unlock this story instantly and join 150,700+ biopharma pros reading Endpoints daily — and it's free. SIGN UP Lei Lei Wu News Reporter With a highly watched FDA decision deadline coming in late January, Biogen and Ionis dropped the full data on the Phase III study of their ALS drug tofersen in the New England Journal of Medicine on Wednesday. Biogen is looking for approval for tofersen in a very small subset of ALS patients — some 2%, according to the paper — who have a SOD1 gene mutation, which has previously been linked to ALS. Tofersen is meant to reduce levels of mutant SOD1 proteins. Keep reading Endpoints with a free subscription Unlock this story instantly and join 150,700+ biopharma pros reading Endpoints daily — and it's free. SIGN UP Zachary Brennan Senior Editor Four experts from the FDA’s Oncology Center of Excellence took to the New England Journal of Medicine yesterday to make the case for not only improving the agency’s ability to expeditiously pull dangling accelerated approvals when, on the rare occasion, confirmatory trials fail, but also better building “quality and efficiency into the AA on-ramp.” The timely perspective arrives as Congress has exactly one week left to draft, release and sign off on the reauthorized user fee deals before layoff notices will be sent to drug reviewers. That package, which is likely to hitch a ride with the continuing resolution , may or may not include several policy riders (opposed by Republicans), including one that would allow the FDA to require confirmatory trials to be underway before an AA is granted, and would improve the process by which FDA can withdraw AAs. Read More September 22, 2022 10:36 AM EDTUpdated 12:10 PM Beth Snyder Bulik Senior Editor Wendy Lund is going home – to WPP, that is. Lund is leaving the Merck women’s health spinoff Organon where she is chief communications officer for a newly created role as WPP chief client officer for health and wellness. Before Organon, Lund led GCI Group, a WPP healthcare communications agency, as CEO for 11 years. Lund joins WPP’s group of global client leaders who act as a single point of contact or entry for clients with WPP brands and businesses inside the holding company. and in this case, for the WPP health and wellness business. Keep reading Endpoints with a free subscription Unlock this story instantly and join 150,700+ biopharma pros reading Endpoints daily — and it's free. SIGN UP Amber Tong Senior Editor GSK likes to take pride in being one of the few Big Pharma players still active in antibiotics R&D. And that means keeping tabs on what the field has to offer. In a move to beef up the late-stage pipeline, GSK is licensing a late-stage antibiotic candidate from Spero Therapeutics. In doing so, it’s coming to the rescue of a struggling biotech that’s crumbled in the wake of an FDA rejection and raised doubts about its ability to carry on. Keep reading Endpoints with a free subscription Unlock this story instantly and join 150,700+ biopharma pros reading Endpoints daily — and it's free. SIGN UP

WPP Investments

63 Investments

WPP has made 63 investments. Their latest investment was in Anzu as part of their Series C on March 3, 2022.

CBI Logo

WPP Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

3/30/2022

Series C

Anzu

$20M

No

9

2/2/2021

Series B

Anzu

$9M

No

24

8/6/2019

Series A

Anzu

$6.5M

Yes

5

10/27/2017

Corporate Minority

Subscribe to see more

Subscribe to see more

10

7/26/2017

Series B

Subscribe to see more

$99M

Subscribe to see more

10

Date

3/30/2022

2/2/2021

8/6/2019

10/27/2017

7/26/2017

Round

Series C

Series B

Series A

Corporate Minority

Series B

Company

Anzu

Anzu

Anzu

Subscribe to see more

Subscribe to see more

Amount

$20M

$9M

$6.5M

$99M

New?

No

No

Yes

Subscribe to see more

Subscribe to see more

Co-Investors

Sources

9

24

5

10

10

WPP Portfolio Exits

25 Portfolio Exits

WPP has 25 portfolio exits. Their latest portfolio exit was Within on October 29, 2021.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

10/29/2021

Acquired

$99M

7

5/25/2021

Acquired

$99M

16

1/14/2021

Acquired

$99M

12

12/17/2020

Acquired

Subscribe to see more

$99M

Subscribe to see more

10

7/7/2020

Merger

Subscribe to see more

$99M

Subscribe to see more

10

Date

10/29/2021

5/25/2021

1/14/2021

12/17/2020

7/7/2020

Exit

Acquired

Acquired

Acquired

Acquired

Merger

Companies

Subscribe to see more

Subscribe to see more

Valuation

$99M

$99M

$99M

$99M

$99M

Acquirer

Subscribe to see more

Subscribe to see more

Sources

7

16

12

10

10

WPP Acquisitions

49 Acquisitions

WPP acquired 49 companies. Their latest acquisition was Newcraft on September 01, 2022.

Date

Investment Stage

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Total Funding

Note

Sources

9/1/2022

$99M

Acquired

13

7/18/2022

$99M

Acquired

2

6/30/2022

$99M

Acquired

3

2/22/2022

Other

Subscribe to see more

$99M

$99M

Subscribe to see more

10

12/6/2021

Subscribe to see more

$99M

Subscribe to see more

10

Date

9/1/2022

7/18/2022

6/30/2022

2/22/2022

12/6/2021

Investment Stage

Other

Companies

Subscribe to see more

Subscribe to see more

Valuation

$99M

$99M

$99M

$99M

$99M

Total Funding

$99M

Note

Acquired

Acquired

Acquired

Subscribe to see more

Subscribe to see more

Sources

13

2

3

10

10

WPP Partners & Customers

10 Partners and customers

WPP has 10 strategic partners and customers. WPP recently partnered with Vatom on August 8, 2022.

Date

Type

Business Partner

Country

News Snippet

Sources

8/17/2022

Vendor

United States

Award winning digital agency YONDER announces key partnership commitment with leading Web3 platform Vatom

With this partnership , Vatom will become the core Web3 platform for YONDER 's Immersive Web and Smart NFT service offering .

1

5/5/2022

Partner

United States

WPP Partners With Epic Games to Evolve Metaverse Offer

Following its partnership announcement with Lego to develop a metaverse , Epic Games has agreed to partner with WPP to help them deliver a digital experience for brands in that space .

3

2/17/2022

Client

Switzerland

Migros selects WPP to help revolutionise its commerce offer

In Team Connect we have found the right partner for our transformation journey and now have the chance to build something completely innovative : a truly integrated and highly agile team with the best experts that WPP has to offer . ''

1

2/1/2022

Supplier

United States

Subscribe to see more

Subscribe to see more

10

11/25/2021

Partner

United States

Subscribe to see more

Subscribe to see more

10

Date

8/17/2022

5/5/2022

2/17/2022

2/1/2022

11/25/2021

Type

Vendor

Partner

Client

Supplier

Partner

Business Partner

Country

United States

United States

Switzerland

United States

United States

News Snippet

Award winning digital agency YONDER announces key partnership commitment with leading Web3 platform Vatom

With this partnership , Vatom will become the core Web3 platform for YONDER 's Immersive Web and Smart NFT service offering .

WPP Partners With Epic Games to Evolve Metaverse Offer

Following its partnership announcement with Lego to develop a metaverse , Epic Games has agreed to partner with WPP to help them deliver a digital experience for brands in that space .

Migros selects WPP to help revolutionise its commerce offer

In Team Connect we have found the right partner for our transformation journey and now have the chance to build something completely innovative : a truly integrated and highly agile team with the best experts that WPP has to offer . ''

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Sources

1

3

1

10

10

WPP Team

51 Team Members

WPP has 51 team members, including , .

Name

Work History

Title

Status

Steve Madincea

Founder

Current

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Name

Steve Madincea

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Work History

Title

Founder

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Status

Current

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

You May Also Like

I
Inspur International

Inspur International distributes, sources, and resells IT products. It is based in Hong Kong.

E
Encora

Encora, formerly known as Indecomm Digital Services, provides software development solutions for Mobility, Big Data and Analytics, Cloud, Machine Learning, UI/UX, IoT, and Test Automation.On December 12, 2019, Indecomm Digital Services was acquired by Avantica Technologies. The terms of the transaction were not disclosed.

E
Emergn

Emergn is a global insurance core system software provider, with independent research and development of insurance core system capabilities, and is committed to empowering insurance companies to become insurance technology companies.

E
Estafet

Estafet is an integration and data insight consultancy company. It is specializes in startups within the fintech, biotech and datatech industries, applying its experience of large enterprises to smaller, growing businesses. It delivers cloud-based solutions through individuals, project teams, or as a managed service. It was founded in 2001 and is based in Richmond, United Kingdom.

Perficient Logo
Perficient

Perficient (NASDAQ: PRFT) is a digital transformation consulting firm. It delivers vision, execution, and value with digital experience, business optimization, and industry solutions. The company was founded in 1997 and is based in St. Louis, Missouri.

Thoughtworks Logo
Thoughtworks

Thoughtworks (NASDAQ: TWKS) provides technology consultancy that integrates strategy, design and engineering. It caters its services to automotive, healthcare & life science, public sector, cleantech energy and utilities, media and publishing, retail and e-commerce, financial services and insurance, not-for-profit, travel and transport sectors. The company was founded in 1993 and is based in Chicago, Illinois.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.